63996 Efficacy and safety of tildrakizumab for the treatment of obese patients with moderate-to-severe plaque psoriasis: Post hoc analysis of reSURFACE 1 and reSURFACE 2

Mark Lebwohl; Andrew Blauvelt; Jerry Bagel; Ranga Gogineni; Christopher Em Griffiths

doi:10.1016/j.jaad.2025.05.742

Article2025

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity

Mark Lebwohl, Jerry Bagel, Ranga Gogineni, Christopher Em Griffiths

Article2023

Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2

Alan M. Menter, Zoe Draelos, Jayme Heim, Ranga Gogineni, Christopher Em Griffiths

Article2023

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Alexander Egeberg, Joseph F. Merola, Knut Schäkel, L. Puig, Patrick Mahar, Isabella Yali Wang, Imre Pávó, Christopher Schuster, Christopher Em Griffiths

Corrigendum2023

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Alexander Egeberg, Joseph F. Merola, Knut Schäkel, L. Puig, Patrick Mahar, Isabella Yali Wang, Imre Pávó, Christopher Schuster, Christopher Em Griffiths

Article2018

AB0912 Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 voyage 1 trial

Christopher Em Griffiths, Kim Papp, Alexa B. Kimball, B. Randazzo, Yasmine Wasfi, S. Li, Yaung‐Kaung Shen, Andrew Blauvelt

63996 Efficacy and safety of tildrakizumab for the treatment of obese patients with moderate-to-severe plaque psoriasis: Post hoc analysis of reSURFACE 1 and reSURFACE 2

Discussion(0)

Related publications

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity

Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

AB0912 Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 voyage 1 trial